• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >CTLA-4 Blockade-Based Immunotherapy in Prostate Cancer
【24h】

CTLA-4 Blockade-Based Immunotherapy in Prostate Cancer

机译：基于CTLa-4阻断的前列腺癌免疫治疗

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This research project investigated immunotherapy for prostate cancer. Specifically, we explored the use of Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) in combination with blockade of a T cell inhibitory molecule called Cytotoxic T-Lymphocyte-Associated Molecule-4 (CTLA-4). We studied repetitive dosing of an anti-CTLA-4 antibody in combination with subcutaneous GM-CSF to determine the safety of this combination. Concomitantly, peripheral blood was being collected from patients to evaluate the immune response generated. The original plan was to move this combination therapy into a phase II trial to look at effects on PSA and other clinical endpoints in patients failing prior vaccination for prostate cancer. This is not possible for a number of reasons. The significant autoimmune toxicity observed (which appears required for an anti-tumor effect) may preclude administration of this combination in prostate cancer patients who are often elderly with comorbidities. Further, the availability of this CTLA-4 antibody is limited. Thus, the current project will end with completion of the phase I trial noted here.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号